Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).

SAN DIEGO -- Finerenone (Kerendia) yielded minimal renal benefit in patients with heart failure with mildly reduced or ...

See related research at KEY POINTS In this issue of CMAJ , Van and colleagues present a cost–utility analysis of several different strategies for introduction of guideline-directed medical therapy ...

An analysis of the FINEARTS-HF trial, which showed finerenone's benefits in heart failure outcomes, shows no significant ...

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.

Abiraterone use for prostate cancer can cause mineralocorticoid excess syndrome (MES; eg, hypertension and hypokalemia). Prednisone mitigates these effects; however, the optimal dose level is unclear.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...